Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Rogier Hintzen, Gavin Giovannoni et al.|The Lancet Neurology|2019Cited by 185
LINGO-1 Regulates Oligodendrocyte Differentiation through the Cytoplasmic Gelsolin Signaling PathwayZhaohui Shao, Sha Mi|Journal of Neuroscience|2017Cited by 42
Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studiesAnn Ranger, Sha Mi|Neurology Neuroimmunology & Neuroinflammation|2017Cited by 30